211813-86-4
物理化学性质
| 储存条件 | -20°C储存 |
| 溶解度 | DMSO: ≥ 150 mg/mL (420.37 mM) |
211813-86-4价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/01/25 | HY-106150B | 211813-86-4 Eniporide hydrochloride | 211813-86-4 | 5mg | 990元 |
| 2024/01/25 | HY-106150B | 211813-86-4 Eniporide hydrochloride | 211813-86-4 | 10mM * 1mLin DMSO | 1089元 |
| 2024/01/25 | HY-106150B | 211813-86-4 Eniporide hydrochloride | 211813-86-4 | 10mg | 1750元 |
常见问题列表
Sodium Channel
There is no significant effects of the Na + /H + exchange inhibitor eniporide on cardiac performance and high energy phosphate content in healthy pig hearts subjected to ischemia/reperfusion induced by crystalloid cardioplegic arrest.
In stage 1, the administration of 100 mg and 150 mg eniporide results in smaller infarct sizes, especially in the angioplasty group. In contrast, in stage 2 there is no difference in the enzymatic infarct size between the three groups. Overall there is no effect of eniporide on clinical outcome (death, cardiogenic shock, heart failure, life-threatening arrhythmias). However, there is a significant reduction of the incidence of heart failure in patients reperfused late (>4 h).